ATHE Alterity publishes latest quarterly earnings report outlining new advancement plans for its lead neurological drug candidate RPID Rapid posts wider Q4 2025 loss than projected with shares gaining modestly on positive investor sentiment Equinix Inc EQIX Poised to Benefit From Tight SupplyDemand Dynamics in the 2026 Singapore Colocation Market